TherapeuticsMD (TXMD), Interview with Robert G. Finizio, CEO

Watch the CEO Signature Series interview with Robert G. Finizio, CEO, Founder and Director of TherapeuticsMD (TXMD).

Robert G. Finizio, CEORobert G. Finizio, CEO

Robert G. Finizio is the Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD. Mr. Finizio has 20 years of healthcare experience and co-founded TherapeuticsMD in 2008, leveraging his entrepreneurial and medication technology background into women’s health. Utilizing the Company’s proprietary technologies, Mr. Finizio is leading TherapeuticsMD through the clinical development and regulatory review for novel hormone therapy products, targeting large, unmet market needs related to menopause management globally. In his current role, Mr. Finizio has raised more than $250 million in capital for the company. Mr. Finizio is a graduate of the University of Miami and taught English in Osaka, Japan before launching his healthcare career, working in the Operating Room for Endoscopy Specialist Incorporated (ESI) in Operational, Sales, and Regional Management roles. After ESI, Mr. Finizio joined OmniCell Technologies a leader in medication management. In 2001, Mr. Finizio co-founded medication and clinical technology vendor CareFusion, selling it to Cardinal Health in 2006.

Company Description:
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The Company’s late stage clinical pipeline includes two phase 3 product candidates: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The Company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Investing Ideas , CEOs
Referenced Symbols: TXMD

More from Nasdaq CEO Signature Series



Nasdaq CEO Signature Series


Research Brokers before you trade

Want to trade FX?